ArticleACS pharmacology & translational science2026
Safety and Efficacy of Adebrelimab plus Apatinib Combined with Hepatic Artery Infusion Chemotherapy for the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combined therapy of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) is now an approved first-line approach for unresectable hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen (oxaliplatin, fluorouracil, and leucovorin) has also shown promising outcomes for advanced HCC. However, the efficacy of these two therapeutic strategies remains to be further improved. This retrospective study evaluated the safety and the efficacy of combining adebrelimab (a PD-L1 inhibitor), apatinib (a TKI), and FOLFOX-HAIC for unresectable HCC. The medical records of unresectable HCC patients who received adebrelimab, apatinib, and FOLFOX-HAIC from March 2023 to November 2023 at the First Affiliated Hospital of Sun Yat-sen University (FAH-SYSU) were retrospectively reviewed. Safety was assessed by the frequency and severity of adverse events (AEs), and efficacy was evaluated by tumor response criteria including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). A total of 19 patients were enrolled. There was no treatment-related death. The most frequent grade ≥ 3 treatment-related AEs were increased ALT/AST (47.4%) and thrombocytopenia (15.8%). The ORR was 26.3% and 57.9%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.